Operator Good afternoon, ladies and gentlemen, and welcome to the INOVIO Pharmaceuticals fourth quarter 2024 financial ...

In a report released yesterday, Gregory Renza from RBC Capital maintained a Hold rating on Inovio Pharmaceuticals (INO – Research Report), with ...

This was the stock's second consecutive day of losses.

Q4 2024 Management View CEO Jacqui Shea highlighted that Inovio remains committed to transforming into a commercial-stage company, with a primary focus on advancing INO-3107, a DNA medicine for ...

RBC Capital lowered the firm’s price target on Inovio (INO) to $5 from $6 and keeps a Sector Perform rating on the shares. The company ...

Inovio Pharmaceuticals, Inc. (NASDAQ:INO – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by ...

INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and ...

expressed DMAbs successfully bound to the SARS-CoV-2 Spike protein receptor-binding domain (RBD), confirming functional activity through week 72 (PRNewsfoto/INOVIO Pharmaceuticals, Inc.) "This ...

Shares of Inovio Pharmaceuticals stock opened at $1.98 on Wednesday. The company has a market capitalization of $51.68 million, a PE ratio of -0.94 and a beta of 0.89. Inovio Pharmaceuticals has a ...

Inovio Pharmaceuticals Inc. closed 86.91% short of its 52-week high of $14.75, which the company reached on April 1st.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...